Johnson & Johnson MedTech announced on 7 November that the FDA has approved its Varipulse platform for treating drug refractory paroxysmal atrial fibrillation.
AFib is the most common type of cardiac arrythmia, affecting more than 8 million people in the US and more than 50 million people worldwide. About one-third of patients with...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?